OBJECTIVE: Our objective for this study was to examine the impact of the modern management of intraocular retinoblastoma on the patient and the family. METHODS: This study comprises a retrospective, noncomparative case series of 25 consecutive patients with multifocal, intraocular retinoblastoma that was treated with primary systemic chemotherapy. Medical charts were reviewed, and the following data were extracted: patients' age and gender, laterality of disease, and Reese-Ellsworth classification of each eye as well as the number of central venous lines placed, cycles of chemotherapy received, outpatient appointments, examinations under anesthesia, focal therapies administered, computed tomography/MRI, radiation treatments, anesthetic procedures administered, and miles traveled. RESULTS: Twenty patients with bilateral and 5 with unilateral intraocular retinoblastoma (median age: 9.3 months) had 895 outpatient appointments and underwent 698 examinations under anesthesia with 230 focal therapies, 347 days of radiotherapy, 226 computed tomography scans/MRIs, and 38 central venous line placements. A total of 1272 anesthetic procedures (median: 50) were performed with no major complication. In all, patients traveled 822312 miles (median: 22214 miles) to receive their care. The median follow-up was 82 months. CONCLUSIONS: Successful retinoblastoma management requires close surveillance, aggressive consolidation, and numerous anesthetic procedures, all of which the patients and the families must endure. There is a significant impact on the patient, the family, and hospital resources.
OBJECTIVE: Our objective for this study was to examine the impact of the modern management of intraocular retinoblastoma on the patient and the family. METHODS: This study comprises a retrospective, noncomparative case series of 25 consecutive patients with multifocal, intraocular retinoblastoma that was treated with primary systemic chemotherapy. Medical charts were reviewed, and the following data were extracted: patients' age and gender, laterality of disease, and Reese-Ellsworth classification of each eye as well as the number of central venous lines placed, cycles of chemotherapy received, outpatient appointments, examinations under anesthesia, focal therapies administered, computed tomography/MRI, radiation treatments, anesthetic procedures administered, and miles traveled. RESULTS: Twenty patients with bilateral and 5 with unilateral intraocular retinoblastoma (median age: 9.3 months) had 895 outpatient appointments and underwent 698 examinations under anesthesia with 230 focal therapies, 347 days of radiotherapy, 226 computed tomography scans/MRIs, and 38 central venous line placements. A total of 1272 anesthetic procedures (median: 50) were performed with no major complication. In all, patients traveled 822312 miles (median: 22214 miles) to receive their care. The median follow-up was 82 months. CONCLUSIONS: Successful retinoblastoma management requires close surveillance, aggressive consolidation, and numerous anesthetic procedures, all of which the patients and the families must endure. There is a significant impact on the patient, the family, and hospital resources.
Authors: Aman Khurana; Christina A Eisenhut; Wenshuai Wan; Katayoon B Ebrahimi; Chirag Patel; Joan M O'Brien; Kristen Yeom; Heike E Daldrup-Link Journal: Eur Radiol Date: 2012-11-18 Impact factor: 5.315
Authors: Iyad Sultan; Matthew W Wilson; Ibrahim Nawaiseh; Mustafa Mehyar; Saamir Kharma; Mohammed Al-Qudimat; Ribhi Hazin; Arwa Alalami; Imad Jaradat; Maysa Al-Husseini; Ghadeer Abdeen; Carlos Rodriguez-Galindo; Ibrahim Qaddoumi Journal: Int Ophthalmol Date: 2010-04-28 Impact factor: 2.031
Authors: Adam L Green; Murali Chintagumpala; Mark Krailo; Bryan Langholz; Daniel Albert; Ralph Eagle; Myles Cockburn; Patricia Chevez-Barrios; Carlos Rodriguez-Galindo Journal: Ophthalmology Date: 2016-06-01 Impact factor: 12.079
Authors: Julia Balaguer; Matthew W Wilson; Catherine A Billups; John Mancini; Barrett G Haik; Ibrahim Qaddoumi; Joseph D Khoury; Carlos Rodriguez-Galindo Journal: Pediatr Blood Cancer Date: 2009-03 Impact factor: 3.167